Pharmaceutical Distribution: approx. 70%
Healthcare Services: approx. 20%
IT Solutions for Healthcare: approx. 10%

TOP 3 Markets:
Japan: approx. 85%
China: approx. 10%
South Korea: approx. 5%

Toho Holdings Co., Ltd. generates the majority of its revenue from pharmaceutical distribution, which accounts for approximately 70% of total revenue. This includes the distribution of medications and medical products to pharmacies and hospitals.

Another significant portion of revenue comes from healthcare services, making up about 20%. This includes services in the field of health prevention and consultation.

The IT solutions for healthcare sector contribute around 10% to the revenue and include software solutions for pharmacies and medical facilities.

Geographically, Japan is the main market for Toho Holdings, accounting for approximately 85% of total revenue. China and South Korea follow as important foreign markets with 10% and 5%, respectively. These markets offer potential for further growth, especially due to the increasing demand for healthcare services and products.

Production Sites: Mainly in Japan

Toho Holdings Co., Ltd. is a Japanese company specializing in wholesale and distribution of pharmaceutical products. The production of products distributed by Toho Holdings is mainly carried out in Japan, as the company primarily acts as a distributor and not as a primary manufacturer.

Toho Holdings collaborates closely with various pharmaceutical manufacturers to distribute their products. The production facilities of these manufacturers are also mainly located in Japan, which facilitates logistics and distribution within the country.

Revenue Growth: Estimated at 5-7% annually (2026, based on industry trends)

Toho Holdings Co., Ltd. is pursuing a strategy focused on diversification and digitalization to secure future growth. The company is increasingly investing in expanding its business in the healthcare services sector, including the development of digital platforms to enhance efficiency and customer engagement.

Another key focus is on international expansion, particularly in Asian markets, to capitalize on the growing demand for pharmaceutical products and services. Through strategic partnerships and acquisitions, Toho Holdings plans to strengthen its market presence and tap into new revenue streams.

Additionally, the company is prioritizing sustainability and innovation to remain competitive in the long term. This includes investments in eco-friendly technologies and optimizing supply chains to reduce costs and environmental impact.

Main raw materials: Pharmaceutical active ingredients, medical devices

Countries of origin: China, India, Germany, USA

Toho Holdings Co., Ltd. is a leading company in the field of pharmaceutical wholesale. The company mainly imports pharmaceutical active ingredients and medical devices needed for the manufacturing and distribution of pharmaceuticals.

China and India are significant suppliers of pharmaceutical active ingredients as they are leading producers in this field worldwide. Germany and the USA are important partners for importing high-quality medical devices and specialized pharmaceutical products.

This diversification in sourcing enables Toho Holdings to offer a wide range of products while benefiting from the cost advantages and quality of international suppliers.

Market Share: 12% (2025, estimated)
ROE (Return on Equity): 8.5% (2025)
EBITDA Margin: 4.2% (2025)

Toho Holdings Co., Ltd. has a significant competitive advantage in the Japanese pharmaceutical wholesale market, supported by a stable market share of approximately 12%. The competitive advantage stems from a well-established distribution network and strong relationships with pharmacies and hospitals.

The EBITDA margin of 4.2% indicates that the company operates efficiently, despite being in an industry typically characterized by low margins. The ROE of 8.5% suggests that Toho Holdings is able to maintain its return on equity at a solid level, indicating effective use of its equity.

Overall, Toho Holdings benefits from a stable market position and operational efficiency, providing the company with a sustainable competitive advantage.

Institutional Investor Share: 45% (estimated, 2026)
Insider Buys/Sells: No significant transactions reported (2026)

The institutional investor share in Toho Holdings Co., Ltd. is estimated to be around 45%. This demonstrates a strong confidence from institutional investors in the company, which often indicates stable financial performance and positive future prospects.

In 2026, no significant insider transactions were reported. This could suggest that the management and other insiders are satisfied with the current company strategy and see no need to change their positions.

Market share of Toho Holdings Co., Ltd.: 12% (estimated for 2026)

Top competitors and their market shares:

1. McKesson Corporation: 18%
2. Cardinal Health, Inc.: 16%
3. AmerisourceBergen Corporation: 15%
4. Toho Holdings Co., Ltd.: 12%
5. Medipal Holdings Corporation: 10%
6. Suzuken Co., Ltd.: 9%
7. Alfresa Holdings Corporation: 8%
8. Sinopharm Group Co., Ltd.: 7%
9. Phoenix Group Holdings: 5%
10. Celesio AG: 4%

Moat of Toho Holdings Co., Ltd.:

Toho Holdings Co., Ltd. has a moderate moat, mainly characterized by its strong presence in the Japanese market and established relationships with pharmacies and hospitals. The logistical infrastructure and the ability to efficiently distribute a wide range of pharmaceutical products also contribute to this advantage.

Compared to leading international competitors like McKesson or Cardinal Health, which have larger global networks and more extensive resources, the moat of Toho Holdings is less pronounced. These competitors often have a greater advantage due to their economies of scale and their ability to operate in multiple markets simultaneously.

However, Toho Holdings can maintain a certain competitive edge through its local market knowledge and adaptability to specific regulatory requirements in Japan. Nevertheless, the pressure from international and regional competitors looking to expand into Asian markets also persists.

Revenue growth: 4.5% (2025) Net income growth: 3.2% (2025) Market share in the Japanese pharmaceutical wholesale trade: 15% (2025)

Toho Holdings Co., Ltd. is a significant player in the Japanese pharmaceutical wholesale trade. In 2025, the company recorded a revenue growth of 4.5%, attributed to stable demand in the healthcare sector and an effective supply chain strategy. Net income grew by 3.2%, indicating improved operational efficiency and cost-cutting measures.

Toho Holdings' market share in the Japanese pharmaceutical wholesale trade is approximately 15%, making the company one of the leading providers in this sector. This strong market position enables Toho Holdings to benefit from long-term trends such as Japan's aging population and increasing demand for healthcare services.

In summary, Toho Holdings represents an attractive investment opportunity due to its solid financial performance, strong market position, and favorable demographic trends in the healthcare sector. However, investors should also consider macroeconomic risks and regulatory changes in the healthcare sector that could impact business potential.

Dividend Yield: 2.5% (estimated for 2026)

Dividend History: Continuous payout over the last 5 years

Toho Holdings Co., Ltd. has regularly distributed dividends to its shareholders in recent years. The dividend yield is currently around 2.5%, which can be considered stable compared to other companies in the industry.

The reliability of dividend payment is supported by the company's solid financial performance and its conservative payout policy. Historically, Toho Holdings has also maintained its dividends in economically challenging times, indicating a strong financial foundation and a sustainable business model.